The miR-21 potential of serving as a biomarker for liver diseases in clinical practice

The role of miR-21 in the pathogenesis of various liver diseases, together with the possibility of detecting microRNA in the circulation, makes miR-21 a potential biomarker for noninvasive detection. In this review, we summarize the potential utility of extracellular miR-21 in the clinical management of hepatic disease patients and compared it with the current clinical practice. MiR-21 shows screening and prognostic value for liver cancer. In liver cirrhosis, miR-21 may serve as a biomarker for the differentiating diagnosis and prognosis. MiR-21 is also a potential biomarker for the severity of hepatitis. We elucidate the disease condition under which miR-21 testing can reach the expected performance. Though miR-21 is a key regulator of liver diseases, microRNAs coordinate with each other in the complex regulatory network. As a result, the performance of miR-21 is better when combined with other microRNAs or classical biomarkers under certain clinical circumstances.

Download Full-text

The emerging role of ferroptosis in non-cancer liver diseases: hype or increasing hope?

Cell Death and Disease ◽

10.1038/s41419-020-2732-5 ◽

2020 ◽

Vol 11 (7) ◽

Cited By ~ 5

Author(s):

Lihong Mao ◽

Tianming Zhao ◽

Yan Song ◽

Lin Lin ◽

Xiaofei Fan ◽

...

Keyword(s):

Cell Death ◽

Liver Diseases ◽

Therapeutic Strategy ◽

Kidney Injury ◽

Hepatic Disease ◽

Therapeutic Concept ◽

Regulated Cell Death ◽

Dependent Form ◽

Molecular Machinery

Abstract Ferroptosis is an iron- and lipotoxicity-dependent form of regulated cell death (RCD). It is morphologically and biochemically distinct from characteristics of other cell death. This modality has been intensively investigated in recent years due to its involvement in a wide array of pathologies, including cancer, neurodegenerative diseases, and acute kidney injury. Dysregulation of ferroptosis has also been linked to various liver diseases and its modification may provide a hopeful and attractive therapeutic concept. Indeed, targeting ferroptosis may prevent the pathophysiological progression of several liver diseases, such as hemochromatosis, nonalcoholic steatohepatitis, and ethanol-induced liver injury. On the contrary, enhancing ferroptosis may promote sorafenib-induced ferroptosis and pave the way for combination therapy in hepatocellular carcinoma. Glutathione peroxidase 4 (GPx4) and system xc− have been identified as key players to mediate ferroptosis pathway. More recently diverse signaling pathways have also been observed. The connection between ferroptosis and other forms of RCD is intricate and compelling, where discoveries in this field advance our understanding of cell survival and fate. In this review, we summarize the central molecular machinery of ferroptosis, describe the role of ferroptosis in non-cancer hepatic disease conditions and discuss the potential to manipulate ferroptosis as a therapeutic strategy.

Download Full-text

Role of FBXL19-AS1 in hepatocellular carcinoma by lncRNA–miRNA–mRNA network analysis and its diagnostic and prognostic value

10.21203/rs.3.rs-44069/v1 ◽

2020 ◽

Cited By ~ 1

Author(s):

Dingdong He ◽

Xiaokang Zhang ◽

Xinyu Zhu ◽

Narayani Maharjan ◽

Yingchao Wang ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Prognostic Value ◽

Clinical Value ◽

Cerna Network ◽

Diagnosis And Prognosis ◽

Potential Biomarker ◽

Viral Carcinogenesis ◽

New Biomarkers ◽

Diagnostic And Prognostic Value

Abstract Background: Hepatocellular carcinoma (HCC) is one of the most common neoplastic diseases worldwide. Available biomarkers are not sensitive enough for the diagnosis of HCC, seeking new biomarkers of HCC is urgent and challenging. The purpose of this study was to investigate the role of F-box and leucine-rich repeat protein 19-antisense RNA 1 (FBXL19-AS1) through competing endogenous RNA (ceRNA) network and its diagnostic and prognostic value in HCC.Methods: A comprehensive strategy of genomic data mining, bioinformatics and experimental validation was used to evaluate the clinical value of FBXL19-AS1 in the diagnosis and prognosis of HCC and to identify the pathways that FBXL19-AS1 may be involved in.Results: FBXL19-AS1 was up-regulated in HCC, and its high expression was associated with TNM stage and poor prognosis of HCC patients. The combined use of plasma FBXL19-AS1 and alpha-fetoprotein (AFP) could prominently improve the diagnostic validity for HCC. FBXL19-AS1 might participate in regulating HCC related pathways, including hepatitis C, hepatitis B, microRNAs in cancer, cell cycle, viral carcinogenesis, and proteoglycans in cancer through ceRNA network.Conclusions: Our findings indicated that FBXL19-AS1 not only serves as a potential biomarker for HCC diagnosis and prognosis, but it may be functionally carcinogenic.

Download Full-text

The Emerging Role of BDNF/TrkB Signaling in Cardiovascular Diseases

Life ◽

10.3390/life11010070 ◽

2021 ◽

Vol 11 (1) ◽

pp. 70

Author(s):

Peng-Zhou Hang ◽

Hua Zhu ◽

Pei-Feng Li ◽

Jie Liu ◽

Feng-Qin Ge ◽

...

Keyword(s):

Cardiovascular Diseases ◽

Metabolic Diseases ◽

Current Evidence ◽

Downstream Signaling ◽

Diagnosis And Prognosis ◽

Potential Biomarker ◽

The Central Nervous System ◽

Artery Disease ◽

Novel Therapeutic Strategies

Brain-derived neurotrophic factor (BDNF) is one of the most abundant neurotrophins in the central nervous system. Numerous studies suggest that BDNF has extensive roles by binding to its specific receptor, tropomyosin-related kinase receptor B (TrkB), and thereby triggering downstream signaling pathways. Recently, growing evidence highlights that the BDNF/TrkB pathway is expressed in the cardiovascular system and closely associated with the development and outcome of cardiovascular diseases (CVD), including coronary artery disease, heart failure, cardiomyopathy, hypertension, and metabolic diseases. Furthermore, circulating BDNF has also been revealed as a new potential biomarker for both diagnosis and prognosis of CVD. In this review, we discuss the current evidence of the emerging role of BDNF/TrkB signaling and address the challenges that remain in translating these discoveries to novel therapeutic strategies for CVD.

Download Full-text

Cerebrospinal Fluid and Blood CX3CL1 as a Potential Biomarker in Early Diagnosis and Prognosis of Dementia

Current Alzheimer Research ◽

10.2174/1567205017666201109095657 ◽

2020 ◽

Vol 17 (8) ◽

pp. 709-721

Author(s):

Agnieszka Kulczyńska-Przybik ◽

Agnieszka Słowik ◽

Piotr Mroczko ◽

Bartłomiej Borawski ◽

Magdalena Groblewska ◽

...

Keyword(s):

Cerebrospinal Fluid ◽

Cognitive Impairment ◽

Early Diagnosis ◽

Crucial Role ◽

Causative Factor ◽

Older Individuals ◽

Blood Concentrations ◽

Diagnosis And Prognosis ◽

Potential Biomarker

Background: A growing body of evidence highlights the crucial role of neuroinflammation and chemokine involvement in cognitive impairment pathophysiology. Fractalkine (CX3CL1) appears to be a relevant causative factor in the development of dementia, particularly at the early stages of the disease. However, limited data are available on the levels of CX3CL1 in the cerebrospinal fluid (CSF) and blood. Additionally, to date, its utility as a biomarker for MCI or AD has not been studied. Objective: The aim of the present study was to evaluate the clinical utility of CX3CL1 in the early diagnosis of cognitive impairment. We also compared the diagnostic usefulness of CX3CL1 with other biomarkers associated with neuroinflammation. Methods: A total of 60 patients with cognitive impairment, including 42 patients with AD and 18 subjects with MCI, as well as 20 cognitively healthy controls were enrolled in the study. CSF and blood concentrations of CX3CL1, CCL-2, and YKL-40 were measured by ELISA. Results: Significantly higher CSF and blood concentrations of CX3CL1 were observed in MCI and AD patients compared to older individuals without cognitive impairment. The increase in the levels of CX3CL1 and YKL-40 in non-demented subjects was associated with MCI. The area under the ROC curve for CX3CL1 in MCI subjects was larger in comparison to classical AD markers. Conclusion: Presented results indicate a crucial role of CX3CL1 in the pathology of cognitive impairment and the potential usefulness of this protein in the early diagnosis of MCI and AD.

Download Full-text

Identify and Validate the Transcriptomic, Functional Network, and Predictive Validity of FBXL19-AS1 in Hepatocellular Carcinoma

Frontiers in Oncology ◽

10.3389/fonc.2020.609601 ◽

2020 ◽

Vol 10 ◽

Author(s):

Dingdong He ◽

Xiaokang Zhang ◽

Xinyu Zhu ◽

Narayani Maharjan ◽

Yingchao Wang ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Functional Network ◽

Clinical Value ◽

Comprehensive Strategy ◽

Diagnosis And Prognosis ◽

Potential Biomarker ◽

Genomic Data Mining ◽

New Biomarkers ◽

Diagnostic And Prognostic Value

Hepatocellular carcinoma (HCC) is one of the most common neoplastic diseases worldwide. Available biomarkers are not sensitive enough for the diagnosis of HCC, hence seeking new biomarkers of HCC is urgent and challenging. The purpose of this study was to investigate the role of F-box and leucine-rich repeat protein 19-antisense RNA 1 (FBXL19-AS1) through a functional network and inquire into its diagnostic and prognostic value in HCC. A comprehensive strategy of genomic data mining, bioinformatics and experimental validation was used to evaluate the clinical value of FBXL19-AS1 in the diagnosis and prognosis of HCC and to identify the pathways in which FBXL19-AS1 might be involved. FBXL19-AS1 was up-regulated in HCC tissues, and its high expression was associated with TNM stage and poor prognosis of HCC patients. The combination of FBXL19-AS1 and alpha-fetoprotein (AFP) in plasma could prominently improve the diagnostic validity for HCC. FBXL19-AS1 might stabilize FBXL19 to reduce the amount of macrophage M1, and then promote the occurrence and development of HCC. Meanwhile, FBXL19-AS1 might participate in regulating HCC related pathways through FBXL19-AS1-miRNA-mRNA network. Our findings indicated that FBXL19-AS1 not only serves as a potential biomarker for HCC diagnosis and prognosis, but also might be functionally carcinogenic.

Download Full-text